Replies to post #316490 on Amarin Corp Plc (AMRN)

[Number sleven]

Marjac, Thanks. That paints a pretty clear picture. Hopefully the en banc petition will be denied.
Sleven,

[Biobillionair]

Marjac:

Amarin's case is very dependent upon GSK v. Teva

100% depends on same legal team but IMO Amarin’s case is much stronger than GSK v. TEVA. Amarin’s case is the poster child for NEVER ALLOWING SKINNY LABELING! Skinny labeling is a regulatory takings claim. If GSK wants to go for a win, they need to simply point out Hikma canceled 3 years of NME, from R-I study and launched cheap rancid API to avoid VASCEPA composition patents. I bet Amarin would give GSK oxidation results to use..... The above FUBAR regulation implodes when you consider VASCEPA.

BB